Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma (Q47130656)

http://europepmc.org/abstract/PMC/5710959

8 January 2018

title

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma (English)

1 reference

http://europepmc.org/abstract/PMC/5710959

8 January 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Amalia De Renzo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alessandro Pulsoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Vittorio Stefoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Cinzia Pellegrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Filippo Gherlinzoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alessandro Broccoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Luigi Rigacci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Caterina Patti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Guido Gini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Donato Mannina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Monica Tani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Chiara Rusconi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alessandra Romano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Anna Vanazzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Barbara Botto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Stefan Hoaus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Gian Matteo Rigolin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Pellegrino Musto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Patrizio Mazza

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Stefano Molica

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Angelo Fama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Fioravante Ronconi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Daniele Vallisa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Patrizia Tosi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Anna Marina Liberati

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Antonello Pinto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Vincenzo Pavone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Maria Paola Bianchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Stefano Volpetti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Maria Cecilia Goldaniga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Corrado Schiavotto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Angelo Michele Carella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Giuseppe Gritti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Livio Trentin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

23 May 2017

1 reference

http://europepmc.org/abstract/PMC/5710959

8 January 2018

published in

Oncotarget

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

91703-91710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

Novel agents in classical Hodgkin lymphoma

11 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Novel treatment concepts in Hodgkin lymphoma.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

The biology of Hodgkin's lymphoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Revised response criteria for malignant lymphoma

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Reporting real-life experience with drugs in lymphoma patients

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Outcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710959

Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29207679

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29207679

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.18114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

PubMed publication ID

29207679

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29207679%20AND%20SRC:MED&resulttype=core&format=json